TY - JOUR
T1 - Myeloid-specific deletion of epsins 1 and 2 reduces atherosclerosis by preventing lrp-1 downregulation
AU - Brophy, Megan L.
AU - Dong, Yunzhou
AU - Tao, Huan
AU - Yancey, Patricia G.
AU - Song, Kai
AU - Zhang, Kun
AU - Wen, Aiyun
AU - Wu, Hao
AU - Lee, Yang
AU - Malovichko, Marina V.
AU - Sithu, Srinivas D.
AU - Wong, Scott
AU - Yu, Lili
AU - Kocher, Olivier
AU - Bischoff, Joyce
AU - Srivastava, Sanjay
AU - Linton, MacRae F.
AU - Ley, Klaus
AU - Chen, Hong
N1 - Funding Information:
These studies were funded in part by National Institutes of Health (NIH) grants R01 HL118676 and R01 HL137229 (H. Chen), American Heart Association (AHA) grant 15EIA22210014 (H. Chen), NIH NRSA F31HL127982 and AHA 15PRE21400010 (M.L. Brophy), AHA 17SDG33630161 (K. Song), AHA 17SDG33410868 (H. Wu), NIH grants P30 RR029846 and P42 ES023716 (S. Srivastava), and NIH grant R01 HL127173 (M.F. Linton, P.G. Yancey, H. Tao).
Publisher Copyright:
© 2018 American Heart Association, Inc.
PY - 2019/1/8
Y1 - 2019/1/8
N2 - Rationale: Atherosclerosis is, in part, caused by immune and inflammatory cell infiltration into the vascular wall, leading to enhanced inflammation and lipid accumulation in the aortic endothelium. Understanding the molecular mechanisms underlying this disease is critical for the development of new therapies. Our recent studies demonstrate that epsins, a family of ubiquitin-binding endocytic adaptors, are critical regulators of atherogenicity. Given the fundamental contribution lesion macrophages make to fuel atherosclerosis, whether and how myeloid-specific epsins promote atherogenesis is an open and significant question. Objective: We will determine the role of myeloid-specific epsins in regulating lesion macrophage function during atherosclerosis. Methods and Results: We engineered myeloid cell-specific epsins double knockout mice (LysM-DKO) on an ApoE-/- background. On Western diet, these mice exhibited marked decrease in atherosclerotic lesion formation, diminished immune and inflammatory cell content in aortas, and reduced necrotic core content but increased smooth muscle cell content in aortic root sections. Epsins deficiency hindered foam cell formation and suppressed proinflammatory macrophage phenotype but increased efferocytosis and anti-inflammatory macrophage phenotype in primary macrophages. Mechanistically, we show that epsin loss specifically increased total and surface levels of LRP-1 (LDLR [low-density lipoprotein receptor]-related protein 1), an efferocytosis receptor with antiatherosclerotic properties. We further show that epsin and LRP-1 interact via epsin's ubiquitin-interacting motif domain. ox-LDL (oxidized LDL) treatment increased LRP-1 ubiquitination, subsequent binding to epsin, and its internalization from the cell surface, suggesting that epsins promote the ubiquitin-dependent internalization and downregulation of LRP-1. Crossing ApoE-/-/LysM-DKO mice onto an LRP-1 heterozygous background restored, in part, atherosclerosis, suggesting that epsin-mediated LRP-1 downregulation in macrophages plays a pivotal role in propelling atherogenesis. Conclusions: Myeloid epsins promote atherogenesis by facilitating proinflammatory macrophage recruitment and inhibiting efferocytosis in part by downregulating LRP-1, implicating that targeting epsins in macrophages may serve as a novel therapeutic strategy to treat atherosclerosis.
AB - Rationale: Atherosclerosis is, in part, caused by immune and inflammatory cell infiltration into the vascular wall, leading to enhanced inflammation and lipid accumulation in the aortic endothelium. Understanding the molecular mechanisms underlying this disease is critical for the development of new therapies. Our recent studies demonstrate that epsins, a family of ubiquitin-binding endocytic adaptors, are critical regulators of atherogenicity. Given the fundamental contribution lesion macrophages make to fuel atherosclerosis, whether and how myeloid-specific epsins promote atherogenesis is an open and significant question. Objective: We will determine the role of myeloid-specific epsins in regulating lesion macrophage function during atherosclerosis. Methods and Results: We engineered myeloid cell-specific epsins double knockout mice (LysM-DKO) on an ApoE-/- background. On Western diet, these mice exhibited marked decrease in atherosclerotic lesion formation, diminished immune and inflammatory cell content in aortas, and reduced necrotic core content but increased smooth muscle cell content in aortic root sections. Epsins deficiency hindered foam cell formation and suppressed proinflammatory macrophage phenotype but increased efferocytosis and anti-inflammatory macrophage phenotype in primary macrophages. Mechanistically, we show that epsin loss specifically increased total and surface levels of LRP-1 (LDLR [low-density lipoprotein receptor]-related protein 1), an efferocytosis receptor with antiatherosclerotic properties. We further show that epsin and LRP-1 interact via epsin's ubiquitin-interacting motif domain. ox-LDL (oxidized LDL) treatment increased LRP-1 ubiquitination, subsequent binding to epsin, and its internalization from the cell surface, suggesting that epsins promote the ubiquitin-dependent internalization and downregulation of LRP-1. Crossing ApoE-/-/LysM-DKO mice onto an LRP-1 heterozygous background restored, in part, atherosclerosis, suggesting that epsin-mediated LRP-1 downregulation in macrophages plays a pivotal role in propelling atherogenesis. Conclusions: Myeloid epsins promote atherogenesis by facilitating proinflammatory macrophage recruitment and inhibiting efferocytosis in part by downregulating LRP-1, implicating that targeting epsins in macrophages may serve as a novel therapeutic strategy to treat atherosclerosis.
KW - Atherosclerosis
KW - Epsin
KW - Inflammation
KW - Macrophage
KW - Mice
UR - http://www.scopus.com/inward/record.url?scp=85061585445&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061585445&partnerID=8YFLogxK
U2 - 10.1161/CIRCRESAHA.118.313028
DO - 10.1161/CIRCRESAHA.118.313028
M3 - Article
C2 - 30595089
AN - SCOPUS:85061585445
SN - 0009-7330
VL - 124
SP - E6-E19
JO - Circulation Research
JF - Circulation Research
IS - 4
ER -